antibody levels – Page 5 – Communicable Diseases Research

Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination

BNT162b2 COVID-19 mRNA 백신 접종 후 6개월 후의 SARS-CoV-2 변이체에 대한 백신 유도 항체 반응

Article

Published on 2022-04-272022-09-11
Journal: Microbiology Spectrum [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술,

Long-Lasting T Cell Responses in BNT162b2 COVID-19 mRNA Vaccinees and COVID-19 Convalescent Patients

BNT162b2 COVID-19 mRNA 백신 및 COVID-19 회복기 환자에서 장기간 지속되는 T 세포 반응

Article

Published on 2022-04-222022-09-11
Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 변종, 진단,

[키워드] Activation acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Alpha antibody antibody levels Beta BNT162b2 Breakthrough infection breakthrough infections Cell mediated immunity coronavirus COVID-19 COVID-19 disease COVID-19 patients cytokine cytokine production delta variant Delta variants Gamma Health care Health care worker health care workers humoral Humoral immunity Infection marker mononuclear cell mononuclear cells more difficult mRNA neutralize Peripheral blood Peripheral blood mononuclear cells persistence Prevent PROTECT question raise report respiratory response SARS-CoV-2 severe acute respiratory syndrome Coronavirus T cell T cell mediated immunity T cell response T cell responses Th1 vaccination Vaccine Vaccines variant variants virus
[DOI] 10.3389/fimmu.2022.869990 PMC 바로가기 [Article Type] Article

Early and strong antibody responses to SARS-CoV-2 predict disease severity in COVID-19 patients

SARS-CoV-2에 대한 초기의 강력한 항체 반응은 COVID-19 환자의 질병 중증도를 예측합니다

Article

Published on 2022-04-152022-09-11
Journal: Journal of Translational Medicine [Category] COVID19(2023년), SARS, 바이오마커, 진단, 치료법,

[키워드] antibody antibody levels Antibody profile Antibody Response Antibody responses Antibody-dependent enhancement Antigen Antigen microarray Biomarker Candidates cell activation Clinical significance correlated COVID-19 COVID-19 patient disease disease severity elicit epidemiological studies exacerbate frequencies Frequency full length healthy controls idea IgA IgA response IgA responses IgE IgG IgM response IgM responses implication levels of antibody mast cell Mast cells Mild disease MOST nonstructural protein nucleocapsid Pathogenesis pathogenesis of COVID-19 Patient patients with COVID-19 peak levels Planning predict Prevalence Prognosis prognostic Protein recent response Result risk S protein SARS-CoV-2 SARS-CoV-2 antigen SARS-CoV-2 antigens sera serological studies SEROLOGICAL STUDY Serum level severe disease severity Spread Support testing antibody the disease the vaccine vaccine candidates virus with mild disease
[DOI] 10.1186/s12967-022-03382-y PMC 바로가기 [Article Type] Article

mRNA vaccination in octogenarians 15 and 20 months after recovery from COVID-19 elicits robust immune and antibody responses that include Omicron

COVID-19에서 회복된 후 15개월 및 20개월 후 80세 여성에서 mRNA 백신 접종은 Omicron을 포함한 강력한 면역 및 항체 반응을 이끌어냅니다

Article

Published on 2022-04-122022-09-11
Journal: Cell Reports [Category] COVID19(2023년), MERS, SARS, 변종, 진단,

[키워드] ACE2 Activation acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 angiotensin angiotensin-converting enzyme 2 antibody Antibody binding antibody levels Antibody Response Antibody responses BNT162b2 BNT162b2 mRNA BNT162b2 mRNA vaccine BNT162b2 vaccine boost Cohort coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 CP: Microbiology cytokine doses elicit Genetic heavy chain high-risk population IgG IGHV IGHV clones immune Immune transcriptome Immunoglobulin Immunoglobulin G include individual Infection interferon Microbiology mRNA vaccination mRNA vaccine naïve individuals naive versus COVID-19-recovered individuals neutralization Neutralizing antibodies neutralizing antibody octogenarian. of BNT162b2 omicron PBMC receiving respiratory response RNA sequencing RNA-Seq robust SARS-CoV-2 SARS-CoV-2 spike-specific single dose sustained transcript Transcriptome vaccination Vaccine vaccine dose vulnerable population
[DOI] 10.1016/j.celrep.2022.110680 PMC 바로가기 [Article Type] Article

Differences in SARS-CoV-2 Vaccine Response Dynamics Between Class-I- and Class-II-Specific T-Cell Receptors in Inflammatory Bowel Disease

염증성 장 질환에서 클래스 I 및 클래스 II 특정 T 세포 수용체 간의 SARS-CoV-2 백신 반응 역학의 차이

Article

Published on 2022-04-082022-09-11
Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 유전자 메커니즘, 진단,

[키워드] Ad26 Ad26.COV2.S Adaptive immune response adaptive immune responses age analyzed antibody antibody levels Antigen antigens BNT162b2 booster bowel characterized clone clones Cohort conditions Critical deficiencies deficiency difference Dynamics expansion Factor HCWs Health care Health care worker health care workers IBD immune factors immune response immune responses Immune-mediated immunodeficiency immunomodulatory induce Infection Inflammatory Inflammatory bowel disease inflammatory disease Inflammatory diseases intestinal mechanism molecular mRNA mRNA vaccine mRNA-1273 vaccine Patient patients protocols response responses robust SARS-CoV-2 SARS-CoV-2 (COVID-19) SARS-CoV-2 vaccination sequenced Sequencing significant difference significant differences Spectrum stratified subset T-cell T-cell receptor T-cell repertoire T-cell Response T-cell responses T-cells TCR the patient Treatment understanding vaccination vaccination response vaccination schedule Vaccine
[DOI] 10.3389/fimmu.2022.880190 PMC 바로가기 [Article Type] Article

Does a humoral correlate of protection exist for SARS-CoV-2? A systematic review

SARS-CoV-2에 대한 체액 보호 상관관계가 있습니까? 체계적인 검토

Article

Published on 2022-04-082022-09-11
Journal: PLoS ONE [Category] COVID19(2023년), SARS, 변종, 진단,

Monitoring of SARS-CoV-2 antibodies using dried blood spot for at-home collection

자택 채취용 건조혈점을 이용한 SARS-CoV-2 항체 모니터링

Article

Published on 2022-04-062022-09-11
Journal: Scientific Reports [Category] COVID19(2023년), SARS, 진단, 치료기술,

Deciphering the quality of SARS-CoV-2 specific T-cell response associated with disease severity, immune memory and heterologous response

질병 중증도, 면역 기억 및 이종 반응과 관련된 SARS-CoV-2 특이적 T 세포 반응의 품질 해독

Article

Published on 2022-04-012022-09-11
Journal: Clinical and Translational Medicine [Category] COVID19(2023년), SARS, 진단, 치료법,

Antibody Response to SARS-CoV-2 Vaccination in Patients following Allogeneic Hematopoietic Cell Transplantation

동종 조혈 세포 이식 후 환자에서 SARS-CoV-2 백신 접종에 대한 항체 반응

Article

Published on 2022-04-012022-09-11
Journal: Transplantation and cellular therapy [Category] COVID19(2023년), SARS, 치료법,

[키워드] age Allogeneic Allogeneic hematopoietic cell transplantation Analysis antibody antibody levels Antibody Response Antibody titer Antibody titers approved BNT162b2 Cell cell transplantation chronic GVHD Cohort conditioning regimen conducted Critical disease domain Efficacy examined Factor Graft-versus-host disease group GVHD had no healthy control healthy controls healthy volunteers hematopoietic Hematopoietic cell transplantation highest homogenous humoral immune response IgA IgG IgM immune response immune responses Immunocompromised patients Immunosuppression information intensity Moderna mRNA mRNA vaccine mRNA vaccines mRNA-1273 nucleocapsid protein pandemic Patient physician reactivity receiving Receptor-binding domain recipient recipients regimen response revaccination S1 and S2 SARS-CoV-2 SARS-CoV-2 antigen SARS-CoV-2 antigens SARS-CoV-2 pandemic SARS-CoV-2 vaccination second dose significantly lower single center spike glycoprotein stratified subunit Switzerland the SARS-CoV-2 the vaccine transplantation Treatment underlying disease vaccination Vaccine waned was performed
[DOI] 10.1016/j.jtct.2022.01.019 PMC 바로가기 [Article Type] Article

Third dose of SARS-CoV-2 vaccination in hemato-oncological patients and health care workers: immune responses and adverse events – a retrospective cohort study

혈액종양 환자 및 의료 종사자에 대한 SARS-CoV-2 백신 3차 접종: 면역 반응 및 부작용 - 후향적 코호트 연구

Article

Published on 2022-04-012022-09-11
Journal: European journal of cancer (Oxford, England : 1990 [Category] COVID19(2023년), SARS, 변종,

[키워드] Adverse adverse event adverse events Analysis anti-S anti-SARS-CoV-2 antibody antibody levels B cell Cancer Care CD19 CD19+ CD56 CD56+ Cell chills Community community hospital Control correlated COVID-19 decrease dose event fatigue follow-up study haematological malignancies haematological malignancy HCW Health Health care Health care worker hospital immune response increasingly Italy local pain longitudinal longitudinal analysis Lower malignancy NK cell oncology other treatment other treatments Patient Patients with cancer patients with haematological Peripheral blood Questionnaires receiving retrieved retrospective cohort study SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 infections SARS-CoV-2 vaccination second vaccination Side-effect solid tumour Spike protein therapy trials Tumours vaccination virus variant waning immunity
[DOI] 10.1016/j.ejca.2022.01.019 PMC 바로가기 [Article Type] Article